Biotechnology and the chicken B cell line DT40

Cytogenetic and Genome Research

Volumn 117, Issue 1-4, 2007, Pages 189-194

  Bachl, J ^a   Caldwell, R B ^a   Buerstedde, J M ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BIOTECHNOLOGY; GENE CONVERSION; GENE MUTATION; GENETIC VARIABILITY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT;

ANIMALS; B-LYMPHOCYTES; BIOTECHNOLOGY; CELL LINE; CHICKENS; GENE EXPRESSION; GENES, REPORTER; HUMANS; MUTATION;

EID: 34547616840     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103179     Document Type: Article

References (47)

1. Amstutz P, Forrer P, Zahnd C, Pluckthun A: In vitro display technologies: novel developments and applications. Curr Opin Biotechnol 12:400-405 (2001).
2. Arakawa H, Saribasak H, Buerstedde JM: Activation-induced cytidine deaminase initiates immunoglobulin gene conversion and hypermutation by a common intermediate. PLoS Biol 2:E179 (2004).
3. Bornscheuer UT, Pohl M: Improved biocatalysts by directed evolution and rational protein design. Curr Opin Chem Biol 5:137-143 (2001).
4. Buerstedde JM, Takeda S: Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 67:179-188 (1991).
5. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC: Green fluorescent protein as a marker for gene expression. Science 263:802-805 (1994).
6. Chen K, Arnold FH: Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. Proc Natl Acad Sci USA 90:5618-5622 (1993).
7. Dahiyat BI, Mayo SL: De novo protein design: fully automated sequence selection. Science 278:82-87 (1997).
8. De Maeyer M, Desmet J, Lasters I: The dead-end elimination theorem: mathematical aspects, implementation, optimizations, evaluation and performance. Meth Mol Biol 143:265-304 (2000).
9. Denepoux S, Razanajaona D, Blanchard D, Meffre G, Capra JD, et al: Induction of somatic mutation in a human B cell line in vitro. Immunity 6:35-46 (1997).
10. Dower WJ, Mattheakis LC: In vitro selection as a powerful tool for the applied evolution of proteins and peptides. Curr Opin Chem Biol 6:390-398 (2002).
11. Farinas ET, Bulter T, Arnold FH: Directed enzyme evolution. Curr Opin Biotechnol 12:545-551 (2001).
12. French DL, Laskov R, Scharff MD: The role of somatic hypermutation in the generation of antibody diversity. Science 244:1152-1157 (1989).
13. Giver L, Arnold FH: Combinatorial protein design by in vitro recombination. Curr Opin Chem Biol 2:335-338 (1998).
14. Graddis TJ, Remmele RL Jr, McGrew JT: Designing proteins that work using recombinant technologies. Curr Pharm Biotechnol 3:285-297 (2002).
15. Green NS, Rabinowitz JL, Zhu M, Kobrin BJ, Scharff MD: Immunoglobulin variable region hypermutation in hybrids derived from a pre-B- and a myeloma cell line. Proc Natl Acad Sci USA 92:6304-6308 (1995).
16. Harayama S: Artificial evolution by DNA shuffling. Trends Biotech 16:76-82 (1998).
17. Hart DJ, Tarendeau F: Combinatorial library approaches for improving soluble protein expression in Escherichia coli. Acta Crystallogr D Biol Crystallogr 62:19-26 (2006).
18. Jestin JL, Kaminski PA: Directed enzyme evolution and selections for catalysis based on product formation. J Biotech 113:85-103 (2004).
19. Kanayama N, Todo K, Takahashi S, Magari M, Ohmori H: Genetic manipulation of an exogenous non-immunoglobulin protein by gene conversion machinery in a chicken B cell line. Nucleic Acids Res 34:e10 (2006).
20. Klepeis JL, Floudas CA: In Silico Protein Design: A combinatorial and global optimization approach. SIAM News 37:1 (2004).
21. Klepeis JL, Floudas CA, Morikis D, Tsokos CG, Argyropoulos E, et al: Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J Am Chem Soc 125:8422-8423 (2003).
22. Kunkel TA: Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 82:488-492 (1985).
23. Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, Patten PA: Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr Opin Biotechnol 12:361-370 (2001).
24. Martin A, Scharff MD: Somatic hypermutation of the AID transgene in B and non-B cells. Proc Natl Acad Sci USA 99:12304-12308 (2002).
25. McKean D, Huppi K, Bell M, Staudt L, Gerhard W, Weigert M: Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci USA 81:3180-3184 (1984).
26. Nera KP, Kohonen P, Narvi E, Peippo A, Mustonen L, et al: Loss of Pax5 promotes plasma cell differentiation. Immunity 24:283-293 (2006).
27. O'Neil KT, Hoess RH: Phage display: protein engineering by directed evolution. Curr Opin Struct Biol 5:443-449 (1995).
28. Pabo C: Molecular technology. Designing proteins and peptides. Nature 301:200 (1983).
29. Petersen-Mahrt SK, Harris RS, Neuberger MS: AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418:99-103 (2002).
30. Rajewsky K: Clonal selection and learning in the antibody system. Nature 381:751-758 (1996).
31. Ruckerl F, Busse B, Bachl J: Episomal vectors to monitor and induce somatic hypermutation in human Burkitt-Lymphoma cell lines. Mol Immunol 43:1645-1652 (2006).
32. Sale JE, Calandrini DM, Takata M, Takeda S, Neuberger MS: Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. Nature 412:921-926 (2001).
33. Saribasak H, Saribasak NN, Ipek FM, Ellwart JW, Arakawa H, Buerstedde JM: Uracil DNA glycosylase disruption blocks Ig gene conversion and induces transition mutations. J Immunol 176:365-371 (2006).
34. Schoetz U, Cervelli M, Wang YD, Fiedler P, Buerstedde JM: E2A expression stimulates Ig hypermutation. J Immunol 177:395-400 (2006).
35. Seo H, Masuoka M, Murofushi H, Takeda S, Shibata T, Ohta K: Rapid generation of specific antibodies by enhanced homologous recombination. Nat Biotechnol 23:731-735 (2005).
36. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317 (1985).
37. Sonoda E, Morrison C, Yamashita YM, Takata M, Takeda S: Reverse genetic studies of homologous DNA recombination using the chicken Blymphocyte line DT40. Phil Trans R Soc Lond B Biol Sci 356:111-117 (2001).
38. Stearns T: Green fluorescent protein. The green revolution. Curr Biol 5:262-264 (1995).
39. Stemmer WP: DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc Natl Acad Sci USA 91:10747-10751 (1994).
40. Stromgaard A, Jensen AA, Stromgaard K: Sitespecific incorporation of unnatural amino acids into proteins. Chembiochem 5:909-916 (2004).
41. Wabl M, Burrows PD, von Gabain A, Steinberg C: Hypermutation at the immunoglobulin heavy chain locus in a pre-B-cell line. Proc Natl Acad Sci USA 82:479-482 (1985).
42. Wang L, Jackson WC, Steinbach PA, Tsien RY: Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci USA 101:16745-16749 (2004).
43. Willats WG: Phage display: practicalities and prospects. Plant Mol Biol 50:837-854 (2002).
44. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR: Making antibodies by phage display technology. Annu Rev Immunol 12:433-455 (1994).
45. Yamazoe M, Sonoda E, Hochegger H, Takeda S: Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair (Amst) 3:1175-1185 (2004).
46. You L, Arnold FH: Directed evolution of subtilisin E in Bacillus subtilis to enhance total activity in aqueous dimethylformamide. Protein Eng 9:77-83 (1996).
47. Zhang W, Bardwell PD, Woo CJ, Poltoratsky V, Scharff MD, Martin A: Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int Immunol 13:1175-1184 (2001).